Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Comparison of adalimumab and secukinumab with respect to short-term efficacy and recurrence in moderate-to-severe psoriasis patients

Bing Wang, Lei You , Xi'ang Yue

Dermatology Department, 970 Hospital of the PLA Joint Logistics Support Force, No. 8, Baoquan Road, Huancui District, Weihai City, Shandong Province, China;

For correspondence:- Lei You Email: leituoyou421016870@163.com Tel:+8615263115341

Accepted: 19 May 2022 Published: 30 June 2022

Citation: Wang B, You L, Yue X. Comparison of adalimumab and secukinumab with respect to short-term efficacy and recurrence in moderate-to-severe psoriasis patients. Trop J Pharm Res 2022; 21(6):1323-1328 doi: 10.4314/tjpr.v21i6.27

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To compare the short-term efficacy and recurrence of moderate-to-severe psoriasis patients through adalimumab and secukinumab.

Methods: A total of 180 patients treated in 970 Hospital of the PLA Joint Logistics Support Force from April 2019 to November 2021 were enrolled in this study. They were assigned to groups A (100 cases treated with secukinumab) and B (80 patients treated with adalimumab). Before and after treatment, the IL-23, TNF-α and 25 (OH) D levels, psoriasis area and severity index (PASI), physician global assessment (PGA), dermatology life quality index (DLQI), compliance with treatment, treatment effectiveness, incidence of adverse reactions, and short-term recurrence were assessed.

Results: After treatment, the TNF-α and IL-23 levels decreased in group A, while the 25 (OH) D level increased (p < 0.05). In comparison to group B, PASI, PGA and DLQI scores in group A were lower (p < 0.05). Compliance in group A was lower (p = 0.002), while total treatment effectiveness was higher (p < 0.001). The incidence of adverse reactions (p =0.004) and frequency of short-term recurrence (p = 0.005) in group A were lower.

Conclusion: The short-term efficacy of secukinumab in moderate-to-severe psoriasis patients is higher than that of adalimumab, while recurrence is lower. Thus, secukinumab shows greater benefits than adalimumab for the treatment psoriasis.

Keywords: Adalimumab, Secukinumab, Psoriasis, Psoriasis Area and Severity Index, Physician global assessment, Dermatology life quality index